Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.65 |
| ▸ | DRD3 | P35462 | 10/20 | 0.65 |
| ▸ | HTR1A | P08908 | 9/20 | 0.65 |
| ▸ | HTR2A | P28223 | 9/20 | 0.65 |
| ▸ | DRD1 | P21728 | 3/20 | 0.65 |
| ▸ | DRD5 | P21918 | 3/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.62 |
| ▸ | HRH1 | P35367 | 6/20 | 0.60 |
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HRH2 | P25021 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6184036 | 0.89 | MAPT (0.58) | DRD2DRD3HTR1AHTR2ADRD1 | |
| SCHEMBL8011318 | 0.89 | DRD2 (0.69) | DRD2DRD3HTR1AHTR2ADRD1 | |
| SCHEMBL5179759 | 0.84 | KDM4E (0.69) | DRD2DRD3HTR1AHTR2ADRD1 | |
| Hydrochloric Acid SCHEMBL11622828 | 0.83 | KDM4E (0.67) | DRD2DRD3HTR1AHTR2ADRD1 | |
| SCHEMBL10995656 | 0.83 | MAPT (0.58) | DRD2DRD3HTR1AHTR2ATMEM97 | |
| SCHEMBL10661045 | 0.83 | DRD2 (0.58) | DRD2DRD3HTR1AHTR2ADRD1 | |
| SCHEMBL2095204 | 0.83 | DRD2 (0.58) | DRD2DRD3HTR1AHTR2ADRD1 | |
| SCHEMBL7653085 | 0.83 | CYP2D6 (0.70) | DRD2DRD3HTR1AHTR2ADRD1 | |
| SCHEMBL8223307 | 0.83 | KDM4E (0.62) | DRD2DRD3HTR1AHTR2ADRD1 | |
| SCHEMBL28918989 | 0.83 | DRD2 (0.58) | DRD2DRD3HTR1AHTR2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273143-B1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | DALIAN WZ PROBIOTICS AD HEALTH CO LTD (CN) | 2025-05-21 | — | — | EP | disclosed |
| US-20240140941-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | DALIAN WZ PROBIOTICS AD HEALTH CO., LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-4273143-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Dalian WZ Probiotics AD Health Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-114685456-B | 2, 5-diketopiperazine compound derivative, preparation method thereof, pharmaceutical composition and application thereof | 大连万众益生大健康有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2022144002-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 大连万众益生大健康有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685456-A | 2, 5-diketopiperazine compound derivative, preparation method thereof, pharmaceutical composition and application thereof | 大连万众益生大健康有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-0911330-B1 | 1-(4-Arylpiperazine-1-y1)-3-(2-oxopyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | COUNCIL SCIENT IND RES (IN) | 2007-12-12 | — | — | EP | disclosed |
| CN-1282643-C | Intermediate for preparing compounds having serotonin-2 receptor antagonistic and alpha-1 blocking action and its preparing method | DAIICHI SUNTORY SEIYAKU CO LTD (JP) | 2006-11-01 | — | — | CN | disclosed |
| EP-0913397-B1 | A proces for the synthesis of 1-(4-Arylpiperazine-1-y1)-3-(2-oxypyrrolidin/piperidin-1-yl)propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | COUNCIL SCIENT IND RES (IN) | 2006-07-05 | — | — | EP | disclosed |
| US-7057036-B2 | Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-06 | — | — | US | disclosed |
| EP-0557526-A1 | PYRROLOAZEPINE COMPOUND | SUNTORY LIMITED (JP) | 1993-09-01 | — | — | EP | disclosed |
| WO-1992022542-A1 | AMINOALKYL-SUBSTITUTED 2-AMINO-5-MERCAPTOTHIADIAZOLES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1992-12-23 | — | — | WO | disclosed |
| US-5130313-A | Central nervous system disorders, cardiovascular disorders or gastrointestinal disorders | RHONE-POULENC SANTE (FR) | 1992-07-14 | — | — | US | disclosed |
| US-5036075-A | Serotonin antagonists | RHONE-POULENC SANTE (FR) | 1991-07-30 | — | — | US | disclosed |
| US-5021420-A | Antiserotonine agents; central nervous system, gastroin-testinal and cardiovascular disorders | RHONE-POULENC SANTE (FR) | 1991-06-04 | — | — | US | disclosed |
| US-4820707-A | TREATING PSYCHOLOGICAL DISORDERS | ADIR ET CIE (FR) | 1989-04-11 | — | — | US | disclosed |
| US-4619929-A | SEDATIVES, HYPOTENSIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1986-10-28 | — | — | US | disclosed |
| EP-0056866-B1 | PHENYLPIPERAZINE DERIVATIVES OF HETERYLPHENOLS AND HETARYLANILINES, THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | BASF Aktiengesellschaft (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0056866-A2 | Phenylpiperazine derivatives of heterylphenols and hetarylanilines, their preparation and their pharmaceutical compositions | BASF Aktiengesellschaft (DE) | 1982-08-04 | — | — | EP | disclosed |
| US-3996361-A | ANTIEDEMATOUS, REDUCING CAPILLARY PERMEABILITY | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140941-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | WEE1, WEE2, CYP51A1 | DRD2 2445/4885DRD3 3654/4885HTR1A 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.